Zurcher Kantonalbank (Zurich Cantonalbank) Immuneering Corp Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$30.1 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 08, 2023	SELL	$3.78 - $10.38 $15,660 - $43,004	-4,143 Reduced 99.88%	5 $0
Q4 2022 Feb 01, 2023	BUY	$4.09 - $15.0 $16,965 - $62,220	4,148 New	4,148 $20,000

Others Institutions Holding IMRX

# of Institutions

Shares Held

9.65M

Call Options Held

Put Options Held

Ken Griffin Citadel Advisors LLC | Chicago, Il

1.88M
Shares

$5.01 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

1.07M
Shares

$2.85 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

953K
Shares

$2.54 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

859K
Shares

$2.29 Million
0.0% of portfolio
Goldman Sachs Group Inc New York, NY

742K
Shares

$1.97 Million
0.0% of portfolio

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $70.2M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account